Preliminary report of a toxicity study of hydroxyurea in sickle cell disease

Archives of Disease in Childhood

Volumn 81, Issue 5, 1999, Pages 437-439

  De Montalembert, M ^a   Begue P ^b   Bernaudin, F ^c   Thuret, I ^d   Bachir, D ^e   Micheau, M ^f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d TIMONE HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Service de Pédiatric B   (France)

Author keywords

Hydroxyurea; Pain; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEG ULCER; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; PARAPLEGIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SICKLE CELL ANEMIA;

EID: 0032736850     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.81.5.437     Document Type: Article

References (15)

1. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-8.
2. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88:1960-4.
3. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematological effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-65.
4. De Montalembert M, Belloy M, Bernaudin F, et al. Three years follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. J Pediatr Hematol Oncol 1997;19:313-18.
5. Olivieri NF, Basran R, Nisbet-Brown, et al. Hydroxyurea in children with sickle cell disease (SCD) [abstract]. Blood 1996;88(suppl 1):621a.
6. Kinney TR. Phase I/II multicenter pediatric trial of hydroxyurea (HUG-KIDS) [abstract]. Blood 1997;90(suppl 1):445a
7. Maier-Redelsperger M, de Montalembert M, Flahaut A, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 1998;91:4472-9.
8. Ohene-Frempong K, Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next? Semin Hematol 1997;34:30-41.
9. Styles LA, Lubin B, Vichinsksy E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89:2554-9.
10. Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol 1994;36:367-72.
11. Horiuchi K, Golden JA, Das SK, et al. Adverse effects of hydroxyurea on growth and development of young mice [abstract]. Blood 1998;92(suppl 1):160a.
12. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
13. Najean Y, Rain JD, for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-7.
14. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocytemia treated with hydroxyurea: high proportion of cases with 17p deletions. Blood 1998;91:616-22.
15. Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyurea in sickle cell disease. Blood 1994;83:1124-8.